Based on the finding that treatment with the α7nAChR agonist PNU-282987 could potentially inhibit DSS-induced colonic inflammatory responses, to address the underlying mechanism, two key signaling pathways, NF-κB and MAPK, which play roles in colitis pathogenesis and are reported to be involved in CAP bioactivity, were next assessed (Yang 2015). This evidence concerns the gene NFKB1 and colitis.